(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012304 A2

(51) International Patent Classification[7]: C07D 487/00

(21) International Application Number:
PCT/EP2004/051457

(22) International Filing Date: 12 July 2004 (12.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP03/50314 16 July 2003 (16.07.2003) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREYNE, Eddy, Jean, Edgard** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutsweg 30, B-2340 Beerse (BE). **LOVE, Christopher, John** [GB/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **COOYMANS, Ludwig, Paul** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VANDERMAESEN, Nele** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BUIJNSTERS, Peter, Jacobus, Johannes, Antonius** [NL/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WILLEMS, Marc** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **EMBRECHTS, Werner, Constant, Johan** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,*

[Continued on next page]

(54) Title: TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS



(I)



(a-1)

(57) Abstract: This invention concerns compounds of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R^1 represents hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} a]kyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonytoxy; or optionally substituted C_{1-6} alkyloxyCl-6alkylcarbonyl; X_1 represents a direct bond; $-(CH_2)_{n3}-$ or $-(CH_2)_{n4}-X_{1a}-X_{1b}-$; R^2 represents optionally substituted C_{3-7}CYCloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatorn selected from 0, S or N; benzoxazolyl or a radical of formula (a-1); X_2 represents a direct bond; $-NR^1-NR^1-(CH_2)_{N3}-$; -0-; -0-$(CH_2)_{n3}-$; -C(=O)-; -C(=O)- $(CH_2)_{n3}-$; -C(=O)-$NR^5-(CH_2)_{n3}-$; -C(=S)-; -S-; $-S(=O)_{n1}-$; $-(CH_2)_{n3}-$; $-(CH_2)_{n4}-X_{1a}-X_{1b}-$; $-X_{1a}-X_{1b}-(CH_2)_{n4}-$; $-S(=O)_{n1}-NR^5-(CH_2)_{n3}-NR^5$_ or $-S(=O)_{n1},-NR^5-(CH_2)_{n3}-$; R^3 represents an optionally substituted 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from 0, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from 0, S or N; R^4 represents hydrogen; halo; hydroxy; optionally substituted C_{1-4}alkyl; optionally substituted C_{2-4}alkenyl or C_{2-4}alkynyl; polyhaloC_{1-3}alkyl; optionally substituted C_{1-4}alkyloxy; polyhaloC_{1-3}alkyloxy; C_{1-4}alkylthio; polyhaloC_{1-3}alkylthio; C_{1-4}alkyloxycarbonyl; C_{1-4}alkylcarbonyloxy; C_{1-4}alkylcarbonyl; polyhaloC_{1-4}alkylcarbonyl; nitro; cyano; carboxyl; NR^9R^{10}; C(=O)NR^9R^{10};-NR^5-C(=O)-NR^9R^{10}; -NR^5-C(=O)-R^5; $-S(=O)_{n1},-R^{11}$ -NR^5-$S(=O)_{n1},-R^{11}$ -S-CN; -NR^5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.

WO 2005/012304 A2

IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.